Ramping up the express stairs: Lisaftoclax in CLL

Nawar Maher; Gianluca GAIDANO

doi:10.1016/j.medj.2025.100921

Ramping up the express stairs: Lisaftoclax in CLL

Nawar Maher
, Gianluca GAIDANO

Department of Translational Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Lisaftoclax, a next-generation BCL2 inhibitor, demonstrated promising efficacy and safety in the phase 1b/2 APG2575CU101 trial by Davids et al. in chronic lymphocytic leukemia (CLL).1 With rapid dose ramp-up and high response rates across monotherapy and combination cohorts, including high-risk and previously treated populations, lisaftoclax shows potential as an effective therapeutic option for CLL, pending validation in larger trials.

Original language	English
Journal	Med
Volume	6
Issue number	12
DOIs	https://doi.org/10.1016/j.medj.2025.100921
Publication status	Published - 2025

Access to Document

10.1016/j.medj.2025.100921

https://hdl.handle.net/11579/221680

Cite this

@article{69483a96d57c4fb29fa9d5f6de8a4048,

title = "Ramping up the express stairs: Lisaftoclax in CLL",

abstract = "Lisaftoclax, a next-generation BCL2 inhibitor, demonstrated promising efficacy and safety in the phase 1b/2 APG2575CU101 trial by Davids et al. in chronic lymphocytic leukemia (CLL).1 With rapid dose ramp-up and high response rates across monotherapy and combination cohorts, including high-risk and previously treated populations, lisaftoclax shows potential as an effective therapeutic option for CLL, pending validation in larger trials.",

author = "Nawar Maher and Gianluca GAIDANO",

note = "Publisher Copyright: {\textcopyright} 2025 Elsevier Inc.",

year = "2025",

doi = "10.1016/j.medj.2025.100921",

language = "English",

volume = "6",

journal = "Med",

issn = "2666-6359",

publisher = "Cell Press",

number = "12",

}

TY - JOUR

T1 - Ramping up the express stairs: Lisaftoclax in CLL

AU - Maher, Nawar

AU - GAIDANO, Gianluca

PY - 2025

Y1 - 2025

N2 - Lisaftoclax, a next-generation BCL2 inhibitor, demonstrated promising efficacy and safety in the phase 1b/2 APG2575CU101 trial by Davids et al. in chronic lymphocytic leukemia (CLL).1 With rapid dose ramp-up and high response rates across monotherapy and combination cohorts, including high-risk and previously treated populations, lisaftoclax shows potential as an effective therapeutic option for CLL, pending validation in larger trials.

AB - Lisaftoclax, a next-generation BCL2 inhibitor, demonstrated promising efficacy and safety in the phase 1b/2 APG2575CU101 trial by Davids et al. in chronic lymphocytic leukemia (CLL).1 With rapid dose ramp-up and high response rates across monotherapy and combination cohorts, including high-risk and previously treated populations, lisaftoclax shows potential as an effective therapeutic option for CLL, pending validation in larger trials.

UR - https://iris.uniupo.it/handle/11579/221680

U2 - 10.1016/j.medj.2025.100921

DO - 10.1016/j.medj.2025.100921

M3 - Article

SN - 2666-6359

VL - 6

JO - Med

JF - Med

IS - 12

ER -

Ramping up the express stairs: Lisaftoclax in CLL

Abstract

Access to Document

Other files and links

Fingerprint

Cite this